Drug Combination Details
| General Information of the Combination (ID: C89957) | |||||
|---|---|---|---|---|---|
| Name | Furanodiene NP Info | + | Germacrone Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Germacrone enhanced furanodiene's anti-proliferative effect. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Impact of fixed-dose combination of germacrone, curdione, and furanodiene on breast cancer cell proliferation. Cell J. Summer 2013;15(2):160-5. | |||
